IRS alleges Bristol Myers Squibb avoided $1.4 billion in taxes; Advisory committee members urge FDA to reject Biogen Alzheimer’s drug; Biden administration rolls out first vaccine confidence TV spots.
Five things for health marketers to know: Thursday, April 1, 2021
Pfizer vaccine proves effective in adolescents; COVID-19 ranks as third leading cause of death in 2020; Former Merck exec set to lead Generate Biomedicines.
Five things for health marketers to know: Wednesday, March 31, 2021
Pfizer to test vaccine version that doesn’t require cold storage; Vaccine hesitancy rates drop; Biden administration to create volunteer network to boost vaccine confidence.
Five things for health marketers to know: Tuesday, March 30, 2021
Nursing homes struggle to vaccinate employees; FDA approves BMS/Bluebird CAR-T therapy Abecma; Biden administration plans to double the number of pharmacy vax sites.
Five things for health marketers to know: Monday, March 29, 2021
Rutgers to require all students to vaccinate for fall classes; Gyroscope Therapeutics wins $148 million Series C for dry-AMD gene therapy; Amazon rolls out vaccination sites for frontline employees.
Five things for health marketers to know: Friday, March 26, 2021
Biden doubles vaccine goal to 200 million doses within his first 100 days; Pfizer starts testing COVID-19 vaccine in young children; Bristol Myers Squibb data on LAG-3 class shows promise in melanoma treatment.
Five things for health marketers to know: Thursday, March 25, 2021
AstraZeneca’s vaccine data deemed questionable and ‘outdated’; Pfizer begins early-stage trial for oral COVID treatment; Novartis cancer drug shows success in Phase III trial.
Five things for health marketers to know: Tuesday, March 23, 2021
AstraZeneca vaccine found to be 79% effective; WHO warns of increasing COVID-19 cases worldwide; FDA questions safety of Pfizer/Eli Lilly’s osteoarthritis drug.
Five things for health marketers to know: Monday, March 22, 2021
HIV/AIDS doctor chosen to head vaccine equity at CDC; U.K. variant threatens to become dominant U.S. strain; Merck’s Keytruda/Lenvima combo passes primary endpoints in Phase III trial.
Loading...
Culture drives the company
Get to know each of these companies by learning about their culture, work/life balance, D&I initiatives and more.
Want to read more?
Please login or register first to view this content.
